EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, today announced the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction. LAMY issued 62,223,000 restricted shares of its Common stock to finalize the deal, consolidating ownership of a highly promising pr ...

Core Viewpoint - BrainStorm Cell Therapeutics Inc. has been granted an extension until June 30, 2025, by the Nasdaq Hearings Panel to regain compliance with certain continued listing standards of The Nasdaq Capital Market [1][2]. Group 1: Compliance and Listing - The company presented its compliance plan to the Nasdaq Hearings Panel on February 25, 2025, which resulted in the granted extension [2]. - The extension reflects the company's commitment to executing its compliance plan within the specified timeframe [2]. Group 2: Company Initiatives - The company is focused on launching a Phase 3b ALS study for its NurOwn® therapy, reducing overall debt, and pursuing strategic partnerships to enhance its pipeline [3]. - BrainStorm is dedicated to maintaining transparency and will provide updates as necessary during this process [3]. Group 3: Technology and Development - BrainStorm is a leading developer of therapies for neurodegenerative diseases, holding exclusive worldwide licensing rights for the NurOwn® technology platform, which produces autologous MSC-NTF cells [4]. - The NurOwn® cells have received Orphan Drug designation from the FDA and EMA for ALS, and the company is planning a confirmatory Phase 3b trial to evaluate safety and efficacy [4]. - The company has also completed a Phase 3 trial for NurOwn in ALS and is advancing studies in progressive multiple sclerosis, supported by grants from CIRM and NMSS [4].